XIncreasing evidence supports a role for CD8+ T cells in multiple sclerosis. In an attempt to isolate the contribution of CD8+ T cells in a murine model of MS, we immunized mice with a dominant CD8 epitope MOG37-46, a truncated version of MOG35-55. The data presented here show mild disease induced with MOG37-46, characterized by lower clinical scores, a decrease in CNS infiltration and a decrease in microglial activation. CD8+ T cells reactive to MOG37-46 are pro-inflammatory and traffic to the CNS; however, the presence of CD4+ T cells elicits more severe disease and sustained inflammation of the CNS.
Introduction
Multiple sclerosis (MS) is a chronic debilitating disease characterized by inflammation of the CNS with subsequent demyelination and axon damage. The origins of disease are largely unknown; however, findings obtained from mouse models and the successes of immunotargeted therapies in human patients provide evidence for an immune component of disease. All arms of the immune system, including CD4+ and CD8+ T cells, B cells, and myeloid cells have been implicated in contributing to demyelinating symptoms (De Jager and Hafler, 2007; Hemmer et al., 2005) . Recently, attention has shifted towards the previously underappreciated contribution of CD8+ T cells to the pathogenesis of the disease. This was prompted by studies in human patients revealing HLA class I gene association with MS, infiltration of oligoclonally expanded CD8+ T cells in CNS lesions, and increased frequency and cytotoxicity of these cells in MS patients (Babbe et al., 2000; Skulina et al., 2004; Zang et al., 2004) . CD8+ T cells can directly recognize antigens on the surface of cells of the central nervous system, since neurons and oligodendrocytes can express MHC class I on their surface, and the levels of MHC molecules are upregulated during inflammation (Galea et al., 2007; Giuliani et al., 2003; Jurewicz et al., 1998; Kawai and Zweiman, 1988; Redwine et al., 2001) .
Interestingly, a regulatory population of cytotoxic CD8+ T cells has also been identified in MS patients. These CD8+ T cells were shown to target CD4+ T cells obtained from the periphery of glatiramer acetate treated MS patient and are associated with a reduced relapse rate and progression of disability (Karandikar et al., 2002; Tennakoon et al., 2006) . Due to these conflicting findings, it is unknown to what degree CD8+ T cells contribute to disease and whether they possess a predominantly effector or regulatory role.
Given the recent focus on the role of CD8+ T cells in multiple sclerosis, there is a need for animal models that can be utilized to study the function of CD8+ T cells in autoimmune demyelination and to develop novel therapies that would target CD8+ T cell function. Initial studies conducted in the murine model of MS, experimental autoimmune encephalomyelitis (EAE), were largely centered on the role of CD4+ T cells in disease. EAE is an inducible model of CD4+ T cell driven demyelination and axon damage. Myelin antigen reactive CD4+ T cells dominate the CNS infiltrate and can initiate disease upon adoptive transfer into naïve animals (Ben-Nun et al., 1996; Mokhtarian et al., 1984; Yura et al., 2001 ). However, CD8+ T cells and macrophages are also recruited into the CNS in this model. Reports from our laboratory and others have identified two CD8+ epitopes, MOG37-46 and MOG44-54, within the immunizing MOG35-55 peptide that is used for disease induction in H-2 b mouse model ( Fig. 1 ) (Ford and Evavold, 2005; Sun et al., 2003) . Immunization with either epitope or transfer of activated CD8+ T cells specific for each epitope can induce disease symptoms (Ford and Evavold, 2005; Sun et al., 2003) . In the same model, several groups reported the presence
